MEDS Overview

Company Update: Oragenics, Inc. has made significant advancements since its $4 million capital raise in September 2024, including improvements to their drug formulation and intranasal delivery device, preparations for Phase II clinical trials in Australia, and the appointment of Janet Huffman as interim CEO.

Future Goals: The company aims to submit an investigational brochure package by Q1 2025, dose the first patient in Australia by early Q2 2025, and submit an IND package for phase IIb clinical trials in the US by Q3 2025, focusing on advancing their treatment ONP-002.

Company Name Change: TRxADE Health, Inc. has officially changed its name to Scienture Holdings, Inc. and its ticker symbol to "SCNX," continuing its operations as a Nasdaq-listed company.

Business Focus: Scienture Holdings, Inc., through its subsidiaries, aims to provide innovative pharmaceutical products across various therapeutic areas, enhancing value for patients and healthcare systems.

Company Name Change: TRxADE Health, Inc. will change its name to Scienture Holdings, Inc., effective September 23, 2024, with stock trading under the new ticker symbol NASDAQ:SCNX.

Business Overview: Scienture is a specialty pharmaceutical company focused on developing unique products across various therapeutic areas, and it recently completed a business combination with TRxADE valued at $103 million.

Leadership Changes at Scienture: TRxADE Health, Inc. has appointed Dr. Narasimhan Mani as President of its subsidiary Scienture, while Shankar Hariharan continues as CEO and Rahul Surana is promoted to Executive VP and COO.

Dr. Mani's Background: Dr. Mani brings over 25 years of experience in the pharmaceutical industry, having held significant roles in various companies, including Kesin Pharma and Amneal Pharmaceuticals, and is expected to enhance Scienture's capabilities as it prepares for upcoming product launches.

Business Combination Announcement: Scienture, Inc. has completed an all-stock business combination with TRxADE Health Inc., valued at $103 million, resulting in a new company named "Scienture Holdings, Inc." that will focus on innovative specialty pharmaceutical products.

Future Plans and Structure: The combined entity aims to enhance patient care through unique product solutions, with current Scienture stockholders expected to own approximately 82.99% of the equity interests post-combination, while TRxADE's leadership will continue to guide the new company.